In this episode we trace the history of aneuploidy screening from the early days of amniocentesis to the modern day serum screening. [email protected] 1987 Cuckle Paper: Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level Other references in no particular order: First-Trimester or Second-Trimester Screening, or Both, for Down's Syndrome INTEGRATED SCREENING FOR DOWN'S SYNDROME BASED ON TESTS PERFORMED DURING THE FIRST AND SECOND TRIMESTERS First Trimester Biochemical Screening for Trisomy 21: The Role of Free Beta hCG, Alpha Fetoprotein and Pregnancy Associated Plasma Protein A First trimester biochemical screening for trisomy 21: the role of free beta heG, alpha fetoprotein and pregnancy associated plasma protein A SOMATIC CHROMOSOMES IN MONGOLISM Screening for Down's Syndrome Contingent screening for Down syndrome completed in the ﬁrst trimester: a multicenter study UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestation Antenatal maternal serumscreening for Down's syndrome: results of a demonstration project Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome Low second trimester maternal serum unconjugated oestriol in pregnancies Down's syndrome Fetal nuchal translucency: ultrasound screening for chromosomal defectsinfirsttrimesterofpregnancy Maternal serum screening for Down's syndrome in early pregnancy Combining maternal age and serum alpha-fetoprotein to predict the risk of Down syndrome Appropriate Biochemical Parameters in First-trimester Screening for Down Syndrome Screening in early pregnancy for pre-eclampsia using Down syndrome Quadruple test markers

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related